IQVIA Holdings Inc. (NYSE:IQV) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts maintain a bullish outlook: IQVIA has a “Moderate Buy” consensus from 17 firms, including 13 buy ratings and one strong-buy rating. The average 12-month price target is $248, while several firms recently raised targets to between $276 and $288.
• Quarterly results exceeded expectations: IQVIA reported earnings of $3.15 per share versus the $3.03 consensus estimate, with revenue of $4.37 billion—up 8.7% year over year and above forecasts.
• Ownership and insider activity were mixed: Institutional investors own 89.62% of the stock, with several funds increasing their positions, while insiders sold 15,581 shares worth approximately $3.8 million over the past 90 days.

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seventeen ratings firms that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $248.00.

Several equities analysts recently weighed in on the company. TD Cowen boosted their price objective on IQVIA from $233.00 to $288.00 and gave the stock a "buy" rating in a research report on Wednesday, July 29th. Barclays reaffirmed an "overweight" rating on shares of IQVIA in a research report on Tuesday, July 28th. Stifel Nicolaus upped their price target on IQVIA from $220.00 to $276.00 and gave the stock a "buy" rating in a report on Wednesday, July 29th. Robert W. Baird increased their price objective on IQVIA from $252.00 to $287.00 and gave the company an "outperform" rating in a research report on Wednesday, July 29th. Finally, HSBC restated a "buy" rating and issued a $240.00 price objective on shares of IQVIA in a research note on Monday, July 6th.

IQVIA Stock Performance

NYSE:IQV opened at $269.33 on Friday. The firm has a market capitalization of $44.33 billion, a PE ratio of 33.42, a PEG ratio of 2.30 and a beta of 1.18. IQVIA has a 1 year low of $154.50 and a 1 year high of $273.88. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm's fifty day simple moving average is $241.49 and its 200 day simple moving average is $198.96.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts' consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business's revenue was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts anticipate that IQVIA will post 11.57 EPS for the current year.

Insider Buying and Selling

In other news, insider W. Richard Staub sold 5,500 shares of the business's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the transaction, the insider owned 13,312 shares in the company, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares in the company, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 15,581 shares of company stock worth $3,796,021. 1.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IQV. National Pension Service lifted its position in IQVIA by 6.6% in the second quarter. National Pension Service now owns 375,973 shares of the medical research company's stock worth $72,646,000 after purchasing an additional 23,411 shares during the period. WINTON GROUP Ltd bought a new stake in IQVIA in the 2nd quarter valued at $5,046,000. Engineers Gate Manager LP acquired a new position in shares of IQVIA in the 2nd quarter valued at $632,000. SVB Wealth LLC raised its stake in shares of IQVIA by 7.4% in the 2nd quarter. SVB Wealth LLC now owns 4,349 shares of the medical research company's stock valued at $840,000 after buying an additional 300 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in shares of IQVIA by 1.2% during the 2nd quarter. NewEdge Advisors LLC now owns 35,788 shares of the medical research company's stock worth $6,915,000 after acquiring an additional 420 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.